Lacosamid Fresenius Kabi (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels in neuronal membranes. This stabilizes hyperexcitable neurons, reducing the likelihood of repetitive firing and thereby decreasing seizure activity.

The specific dose and infusion rate are determined by the prescribing clinician based on the patient’s condition, age, weight, renal and hepatic function, and response to therapy. No fixed dosing regimen is provided here.

Safety data for lacosamide during pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Lacosamide’s unique mechanism—enhancing slow sodium‑channel inactivation—differs from agents like carbamazepine, which target fast inactivation, and levetiracetam, which binds SV2A. This can result in a distinct side‑effect profile and may be advantageous for patients who have not responded to other classes.

The product should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen. Prior to use, inspect the vial for particulate matter and ensure the solution is at room temperature if required for infusion.

Lacosamid Fresenius Kabi is supplied as an intravenous solution. It is administered by slow infusion through a suitable IV line, following the dosing instructions provided by the prescribing clinician and adhering to aseptic technique.

Serious adverse events include cardiac conduction abnormalities such as PR‑interval prolongation, severe skin reactions like Stevens‑Johnson syndrome, suicidal thoughts, and rare cases of anaphylaxis. Patients should be monitored closely for these events, especially during initiation and dose adjustments.

Lacosamid should be avoided in individuals with known hypersensitivity to lacosamide or any component of the formulation, and in patients with significant cardiac conduction disorders that could be worsened by PR‑interval prolongation. Clinicians should assess each patient’s medical history before prescribing.